CCS ASSOCIATES, INC. - REGULATORY SUPPORT FOR LEAD GENE THERAPY CANDIDATES AS A TREATMENT FOR CONGENITAL MYASTHENIC SYNDROMES
Key Details
Description
REGULATORY SUPPORT FOR LEAD GENE THERAPY CANDIDATES AS A TREATMENT FOR CONGENITAL MYASTHENIC SYNDROMES
Context & Analysis
On Aug 27, 2026, Department of Health and Human Services obligated $159,115.55 to CCS ASSOCIATES, INC. for regulatory support for lead gene therapy candidates as a treatment for congenital myasthenic syndromes. The award is classified under NAICS 541690 — OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES. Competition extent: full and open competition after exclusion of sources with 3 offers received. Performance is located in SAN JOSE, CA. The contract is scheduled through Aug 31, 2029. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541690 — related awards are listed below.
Contractor Information
Similar Awards
HEALTHCARE COST AND UTILIZATION PROJECT (HCUP) CLIN 0002 BASE AWARD
NATIONAL OPINION RESEARCH CENTER
$33.7M
SENTINEL 2.0 BRIDGE CONTRACT
HARVARD PILGRIM HEALTH CARE, INC.
$32.9M
MIDS DEVELOPMENT, REEVALUATION AND IMPLEMENTATION OF OUTCOME/EFFICIENCY MEASURES FOR HOSPITAL AND ELIGIBLE CLINICIANS
YALE NEW HAVEN HEALTH SERVICES CORPORATION
$30.9M
INFLUENZA SCIENTIFIC SUPPORT PERSONNEL
CHIPPEWA GOVERNMENT SOLUTIONS, LLC
$24.1M
PROGRAM AND STAFF SUPPORT
GOLDBELT C6, LLC
$23.1M
Stay Updated
Get notified about new opportunities matching your interests.